Abstract: To review and discuss the results from the clinical controlled trials comparing a dipeptidyl peptidase-4 inhibitor with placebo treatment as add-on to insulin treatment with respect to changes in HbA1c, weight, fasting plasma glucose, risk of hypoglycaemia and safety in patients with Type 2 diabetes.